Anti-CADM-140/MDA5 antibody and clinical subsets of dermatomyositis

DOI 参考文献14件
  • Horai Yoshiro
    Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Koga Tomohiro
    Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Fujikawa Keita
    Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Japan
  • Kawakami Atsushi
    Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

この論文をさがす

抄録

The clinical features of dermatomyositis (DM) have a close relationship with myositis-specific antibodies. Clinically amyopathic dermatomyositis (CADM) is a subgroup of DM, which manifests as characteristic skin symptoms compatible with DM, such as Gottron's sign and heliotrope rash with no or mild muscle symptoms. Sometimes, a life-threatening rapidly progressing interstitial lung disease can complicate CADM. In recent years, anti-CADM-140/MDA5 antibodies have been observed in serum obtained from patients with CADM. Thus, measurement of anti-CADM-140/MDA5 antibodies is useful for the diagnosis and prediction of prognosis of patients with CADM.

収録刊行物

参考文献 (14)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ